TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34977553

Group type: EXPERIMENTAL
Intervention: Pharmacists-physicians collaborative coaching intervention delivered over two months through Facebook live sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacists-physicians collaborative coaching intervention
Number of subjects: 0
Study: 34818363

Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS), 2.5 g doses before sleeping on the night before surgery and 2 hours before anesthesia induction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (CNT), no medication preoperatively
Number of subjects: 100
Study: 35500960

Group type: EXPERIMENTAL
Intervention: Routine physical therapy along with Low Intensity Pulsed Ultrasound (LIPUS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Routine physical therapy (Control Group)
Number of subjects: 34
Study: 36143107

Group type: EXPERIMENTAL
Intervention: Hydroponic tomato puree
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional tomato puree
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 33121121

Group type: EXPERIMENTAL
Intervention: Loaded Plyometrics (LP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Unloaded Plyometrics (UP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 38
Study: 35565110

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) prevention program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Delayed treatment group (DTG, waiting list control)
Number of subjects: 27
Study: 616617623

Group type: EXPERIMENTAL
Intervention: Interactive half-day course about information for transition to end-of-life care for physicians and nurses
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (matched hospitals and municipalities)
Number of subjects: 8
Study: 34427549

Group type: EXPERIMENTAL
Intervention: NCD prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34010494

Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (no DCS)
Number of subjects: 152
Study: 33141099

Group type: EXPERIMENTAL
Intervention: Group receiving all texts (comprehensive messages)
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Group receiving basic messages
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Group receiving messages regarding care seeking
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Group receiving messages regarding good home prenatal practices
Number of subjects: 2115

Group type: EXPERIMENTAL
Intervention: Previous cesarean section history
Number of subjects: 2115
Study: 35491682

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (IVK) administered pre-operatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (IVK) administered intra-operatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (IVK) administered post-operatively
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no IVK)
Number of subjects: 200
Study: 34154341

Group type: EXPERIMENTAL
Intervention: Stroke Volume Variation (SVV)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Volume Expansion (VE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic (ROC) curve for SVV
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic (ROC) curve for PPV
Number of subjects: 35
Study: 32564042

Group type: EXPERIMENTAL
Intervention: FED method
Number of subjects: 60

Group type: COMPARATOR
Intervention: FITS method
Number of subjects: 60
Study: 33185166

Group type: EXPERIMENTAL
Intervention: MTX with doxycycline 200mg per day orally
Number of subjects: 160

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 160
Study: 35709509

Group type: EXPERIMENTAL
Intervention: CBL-514 injection at a dose of 2.0 mg/cm2 (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBL-514 injection at a dose of 1.6 mg/cm2 (240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBL-514 injection at a dose of 1.2 mg/cm2 (180 mg)
Number of subjects: 0
Study: 33251840

Group type: EXPERIMENTAL
Intervention: Simple interrupted suture pattern
Number of subjects: 9

Group type: COMPARATOR
Intervention: Simple continuous suture pattern
Number of subjects: 9
Study: 32107526

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 216

Group type: COMPARATOR
Intervention: Deferred ART initiation (24 weeks)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation (≤30 days from EDDI)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Deferred ART initiation (>90 days from EDDI)
Number of subjects: 216
Study: 32674587

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 118

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 118
Study: 36254811

Group type: EXPERIMENTAL
Intervention: Physical health nurse intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 77
Study: 34506326

Group type: EXPERIMENTAL
Intervention: Initial laparotomy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Peritoneal drainage
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Initial laparotomy (with preoperative diagnosis of NEC)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Peritoneal drainage (with preoperative diagnosis of NEC)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Initial laparotomy (with preoperative diagnosis of IP)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Peritoneal drainage (with preoperative diagnosis of IP)
Number of subjects: 310
Study: 35189351

Group type: EXPERIMENTAL
Intervention: Painful conditioning stimulus (12 °C water bath)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonpainful conditioning stimulus (22 °C water bath)
Number of subjects: 54
Study: 34454810

Group type: EXPERIMENTAL
Intervention: Telemonitoring (e-Vita HF platform) instead of face-to-face consultations
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual HF outpatient care
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care combined with the use of the website heartfailurematters.org
Number of subjects: 223
Study: 33492878

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 33470152

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulation restarted after 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulation restarted after 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulation restarted after 4 weeks
Number of subjects: 0
Study: 32430108

Group type: EXPERIMENTAL
Intervention: POCUS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 34651171

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) hydration
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous (IV) hydration
Number of subjects: 51
Study: 34497023

Group type: EXPERIMENTAL
Intervention: Direct Composite Restorations (DCR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Indirect Composite Restorations (ICR)
Number of subjects: 41
Study: 35264347

Group type: EXPERIMENTAL
Intervention: VATS procedure with drainage
Number of subjects: 184

Group type: COMPARATOR
Intervention: TUS-guided pigtail catheter placement and intrapleural therapy with Actilyse and DNase
Number of subjects: 184
Study: 34081259

Group type: EXPERIMENTAL
Intervention: Fat-enlarged axillary lymph nodes visualized on breast MRI
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Size of fat-enlarged nodes in the contralateral axilla identified on breast MRI
Number of subjects: 431
Study: 36130946

Group type: EXPERIMENTAL
Intervention: Neflamapimod 40 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 33172597

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 2084
Study: 32057924

Group type: EXPERIMENTAL
Intervention: High-frequency (5Hz) rTMS stimulation on pre-SMA region
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-frequency (5Hz) rTMS stimulation on M1 region
Number of subjects: 16
Study: 35880801

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy Lifestyle (HL)
Number of subjects: 100
Study: 34106607

Group type: EXPERIMENTAL
Intervention: Genoss DES
Number of subjects: 77

Group type: COMPARATOR
Intervention: Promus Element
Number of subjects: 77
Study: 32726873

Group type: EXPERIMENTAL
Intervention: WeChat-based 'three good things' (3GT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 35063281

Group type: COMPARATOR
Intervention: Paclitaxel 80mg/m2 weekly up to 24 weeks (control)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets twice daily + Cediranib 20mg daily (continuous schedule)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets twice daily + Cediranib 20mg 5 days/week (intermittent schedule)
Number of subjects: 123
Study: 32844807

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 40
Study: 35151415

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and low-dose dexamethasone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Pomalidomide and low-dose dexamethasone (Control)
Number of subjects: 307
Study: 32956630

Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease present
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease present (non-anticoagulated atrial fibrillation)
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Peripheral arterial disease absent
Number of subjects: 4060
Study: 32312065

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Simple tube feeding (STF)
Number of subjects: 41
Study: 33842984

Group type: EXPERIMENTAL
Intervention: Ultracongruent (UC) insert design
Number of subjects: 127

Group type: COMPARATOR
Intervention: Posterior stabilized (PS) design
Number of subjects: 127
Study: 33307657

Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic work (120 days, 3 times a week on a bicycle ergometer)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Traditional strength protocol (120 days, 3 times a week)
Number of subjects: 55
Study: 34506761

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m2) plus uromitexan (200 mg/m2) at days 0, 15, 30, and 60
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 120
Study: 32094016

Group type: EXPERIMENTAL
Intervention: Cardiac catheterisation laboratory without a Medical emergency team
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Post percutaneous coronary intervention
Number of subjects: 75
Study: 35395289

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter defibrillator (WCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 0
Study: 33528369

Group type: EXPERIMENTAL
Intervention: WeChat group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison between WeChat and Control groups
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Satisfaction survey on WeChat management
Number of subjects: 200
Study: 35452861

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 3g administered intra-articular after cementation and prior to capsular closure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 35508352

Group type: EXPERIMENTAL
Intervention: NAT-guided clinical consultation plus usual care
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1080
Study: 34895291

Group type: EXPERIMENTAL
Intervention: TGTG group (Treated with Genetic Test Guide)
Number of subjects: 300

Group type: COMPARATOR
Intervention: TAU group (Treated as Usual)
Number of subjects: 300
Study: 35075022

Group type: EXPERIMENTAL
Intervention: Single-shot caudal morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous narcotic-based anesthesia
Number of subjects: 60
Study: 34454540

Group type: EXPERIMENTAL
Intervention: Oral azacitidine 300 mg once-daily for 14 days in repeated 28-day cycles
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Number of subjects: 469
Study: 32649708

Group type: EXPERIMENTAL
Intervention: Whole milk 3.6% fat + RE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skimmed milk 0.3% fat + RE
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate drink + RE
Number of subjects: 30
Study: 34957954

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 8 U/kg
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 4 U/kg
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 32080847

Group type: EXPERIMENTAL
Intervention: Diversity training focusing on ingroup privilege awareness
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study: 35556335

Group type: EXPERIMENTAL
Intervention: Progressive aerobic cycling exercise for 20-45 min up to 80% of heart rate reserve, 3 days/week for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-aerobic, stretching exercise, 3 days/week for 12 weeks
Number of subjects: 10
Study: 32333883

Group type: EXPERIMENTAL
Intervention: Intervention group (dietary counselling)
Number of subjects: 1116
Study: 34366432

Group type: EXPERIMENTAL
Intervention: WISER intervention
Number of subjects: 481

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 481
Study: 32371073

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using unweighted kappa
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using weighted kappa
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability for noted present symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability for noted absent symptoms
Number of subjects: 100
Study: 36326299

Group type: EXPERIMENTAL
Intervention: Sour cherry concentrate (75 ml twice daily for 2 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 70
Study: 33465768

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Diazepam (in patients with cortical anterior circulation infarction)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo (in patients with cortical anterior circulation infarction)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Diazepam vs. Placebo (in patients with cortical anterior circulation infarction)
Number of subjects: 784
Study: 32681461

Group type: COMPARATOR
Intervention: ASP3652 (1–600 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP3652 (10–300 mg bid and 600 mg qd for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP3652 (single and multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP3652 (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP3652 (single dose with food)
Number of subjects: 0
Study: 35246425

Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (GLI) for 24 months in addition to usual care
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 234
Study: 34583214

Group type: EXPERIMENTAL
Intervention: IFN-curcumin
Number of subjects: 80

Group type: COMPARATOR
Intervention: IFN-placebo
Number of subjects: 80
Study: 33874971

Group type: EXPERIMENTAL
Intervention: Multi-domain responder index (MDRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional clinical trial design
Number of subjects: 0
Study: 32011684

Group type: EXPERIMENTAL
Intervention: Right-truncated Poisson-distributed outcomes
Number of subjects: 0
Study: 35674613

Group type: EXPERIMENTAL
Intervention: T. harzianum with 50 g of NPK treatment (T2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: B. thuringiensis plus 50 g NPK treatment (T3)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: B. thuringiensis with 25 g NPK fertilizer treatment (T5)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Soil inoculation of B. thuringiensis
Number of subjects: 5
Study: 32808394

Group type: EXPERIMENTAL
Intervention: Horse riding simulator (HRS) along with conventional physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study: 35333363

Group type: EXPERIMENTAL
Intervention: Team-based empowered care group
Number of subjects: 2393

Group type: EXPERIMENTAL
Intervention: Empowered care group
Number of subjects: 2393

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 2393

Group type: COMPARATOR
Intervention: Team-based empowered care group vs usual care group
Number of subjects: 2393

Group type: COMPARATOR
Intervention: Team-based empowered care group vs empowered care group
Number of subjects: 2393

Group type: EXPERIMENTAL
Intervention: Attainment of multiple treatment targets
Number of subjects: 2393
Study: 32272501

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA)
Number of subjects: 50
Study: 33908296

Group type: EXPERIMENTAL
Intervention: 250 µg roflumilast
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 µg roflumilast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32036644

Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 1000
Study: 35667389

Group type: EXPERIMENTAL
Intervention: RFA followed by SEMS insertion (RFA+SEMS, n = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: SEMS only (n = 44)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: RFA followed by SEMS insertion (RFA+SEMS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: SEMS only
Number of subjects: 86
Study: 32773431

Group type: EXPERIMENTAL
Intervention: Total resection of the cystic lesion
Number of subjects: 30
Study: 35766037

Group type: EXPERIMENTAL
Intervention: Combination therapy of candesartan and carvedilol plus standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 33651099

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP (8 cycles of 21 days)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Rituximab plus CHOP (6 or 8 cycles)
Number of subjects: 1418
Study: 35988057

Group type: EXPERIMENTAL
Intervention: EPI-589 (500 mg twice daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPI-589 (750 mg twice daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPI-589 (1000 mg single daily dose)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPI-589 (250-1000 mg single doses)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPI-589 under fasting conditions
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EPI-589 under fed conditions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 34742669

Group type: EXPERIMENTAL
Intervention: Group Intervention in OBEsity (IGOBE) program with weekly sessions for six weeks
Number of subjects: 437

Group type: COMPARATOR
Intervention: Usual care therapy (Control Group)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Group Intervention in OBEsity (IGOBE) program
Number of subjects: 437
Study: 33157551

Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer
Number of subjects: 2824
Study: 35742618

Group type: EXPERIMENTAL
Intervention: Judo4Balance program (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (n = 100)
Number of subjects: 200
Study: 32969828

Group type: EXPERIMENTAL
Intervention: Accelerometry data collection using Actigraph GT9X accelerometer
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Activity tracking
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: No other characteristics
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Overall protocol for accelerometry data collection
Number of subjects: 580
Study: 35183768

Group type: EXPERIMENTAL
Intervention: AFI-guided probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 154

Group type: COMPARATOR
Intervention: High-resolution white-light endoscopy (HRWLE) with Seattle protocol biopsies
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 3-biomarker panel (pCLE optical dysplasia, aberrant p53, and aneuploidy)
Number of subjects: 154
Study: 32736592

Group type: EXPERIMENTAL
Intervention: EDP1815 (2 capsules twice daily for up to 7 days, with an option to extend to 14 days)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10mg once daily) and Ambrisentan (5mg once daily for up to 14 days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 125
Study: 33725995

Group type: EXPERIMENTAL
Intervention: Probiotics given orally for 8 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo given orally for 8 weeks
Number of subjects: 192
Study: 33723675

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Instrumental support
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pain interference
Number of subjects: 327
Study: 32051002

Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Living Healthy Together (control condition)
Number of subjects: 120
Study: 33998179

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trans‐scleral diode laser cyclophotocoagulation (TDLC)
Number of subjects: 105